Tibet Weixinkang Medicine Co Ltd (603676) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.009x

Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million ≈ $2.00 Million USD) by net assets (CN¥1.53 Billion ≈ $223.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tibet Weixinkang Medicine Co Ltd (603676) balance sheet quality index to measure how much of total assets are equity-financed.

Tibet Weixinkang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 603676 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
More Provident Funds TA:MPP	-0.116x
MERSEN UNSP.ADR 1/5 EO 2 F:CBE0	N/A
Indointernet Tbk PT JK:EDGE	0.095x
MTY Food Group Inc TO:MTY	0.048x
Shenzhen Refond Optoelectronics Co Ltd SHE:300241	0.014x
Rio2 Ltd V:RIO	-0.051x
MNRB Holdings Bhd KLSE:6459	0.019x
Anhui Huamao Textile Co Ltd SHE:000850	0.117x

Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Tibet Weixinkang Medicine Co Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.48 Billion ≈ $216.04 Million	CN¥185.53 Million ≈ $27.15 Million	0.126x	-53.30%
2024-12-31	CN¥1.39 Billion ≈ $202.73 Million	CN¥372.78 Million ≈ $54.55 Million	0.269x	+40.51%
2023-12-31	CN¥1.34 Billion ≈ $196.13 Million	CN¥256.67 Million ≈ $37.56 Million	0.191x	-5.04%
2022-12-31	CN¥1.22 Billion ≈ $178.61 Million	CN¥246.15 Million ≈ $36.02 Million	0.202x	+26.10%
2021-12-31	CN¥1.07 Billion ≈ $156.17 Million	CN¥170.69 Million ≈ $24.98 Million	0.160x	+17.61%
2020-12-31	CN¥983.21 Million ≈ $143.87 Million	CN¥133.70 Million ≈ $19.56 Million	0.136x	+18.93%
2019-12-31	CN¥930.05 Million ≈ $136.10 Million	CN¥106.34 Million ≈ $15.56 Million	0.114x	+23.41%
2018-12-31	CN¥897.64 Million ≈ $131.35 Million	CN¥83.17 Million ≈ $12.17 Million	0.093x	+25.59%
2017-12-31	CN¥858.04 Million ≈ $125.56 Million	CN¥63.30 Million ≈ $9.26 Million	0.074x	-67.34%
2016-12-31	CN¥459.42 Million ≈ $67.23 Million	CN¥103.79 Million ≈ $15.19 Million	0.226x	-20.48%
2015-12-31	CN¥402.93 Million ≈ $58.96 Million	CN¥114.47 Million ≈ $16.75 Million	0.284x	-31.35%
2014-12-31	CN¥286.28 Million ≈ $41.89 Million	CN¥118.47 Million ≈ $17.34 Million	0.414x	+15.75%
2013-12-31	CN¥247.78 Million ≈ $36.26 Million	CN¥88.59 Million ≈ $12.96 Million	0.358x	--

About Tibet Weixinkang Medicine Co Ltd

SHG:603676 China Drug Manufacturers - Specialty & Generic

Market Cap

$566.73 Million

CN¥3.87 Billion CNY

Market Cap Rank

#11586 Global

#3274 in China

Share Price

CN¥8.90

Change (1 day)

+1.48%

52-Week Range

CN¥8.04 - CN¥13.08

All Time High

CN¥24.05